Amprenavir (BioDeep_00000001890)

 

Secondary id: BioDeep_00000398938

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid

化学式: C25H35N3O6S (505.22464500000007)
中文名称: 安普那韦
谱图信息: 最多检出来源 Homo sapiens(blood) 66.67%

分子结构信息

SMILES: CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
InChI: InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1

描述信息

Amprenavir is only found in individuals that have used or taken this drug. It is a protease inhibitor used to treat HIV infection.Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AE - Protease inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D000995 - Antitubercular Agents
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

同义名列表

15 个代谢物同义名

(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid; (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid; (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate; (3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-1-phenylbutan-2-yl]carbamate; Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate; GlaxoSmithKline brand OF amprenavir; Glaxo wellcome brand OF amprenavir; CHEMBL195725; Vertex VX478; Amprenavir; Agenerase; VX-478; AMP; AMV



数据库引用编号

17 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Amit Roy, Sachidananda Behera, Priyanka H Mazire, Bhavini Kumari, Abhishek Mandal, Bidyut Purkait, Payel Ghosh, Prolay Das, Pradeep Das. The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death. Parasitology international. 2021 Jun; 82(?):102287. doi: 10.1016/j.parint.2021.102287. [PMID: 33515743]
  • Marlies Braeckmans, Joachim Brouwers, Imke Masuy, Cécile Servais, Jan Tack, Patrick Augustijns. The influence of gastric motility on the intraluminal behavior of fosamprenavir. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2020 Jan; 142(?):105117. doi: 10.1016/j.ejps.2019.105117. [PMID: 31682976]
  • Hongfu Lu, Ting Yang, Zhongmiao Xu, Xichen Lin, Qian Ding, Yueting Zhang, Xin Cai, Kelly Dong, Sophie Gong, Wei Zhang, Metul Patel, Royston C B Copley, Jianing Xiang, Xiaoming Guan, Paul Wren, Feng Ren. Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists. Journal of medicinal chemistry. 2018 03; 61(6):2518-2532. doi: 10.1021/acs.jmedchem.7b01854. [PMID: 29406702]
  • Oksana Gerlits, David A Keen, Matthew P Blakeley, John M Louis, Irene T Weber, Andrey Kovalevsky. Room Temperature Neutron Crystallography of Drug Resistant HIV-1 Protease Uncovers Limitations of X-ray Structural Analysis at 100 K. Journal of medicinal chemistry. 2017 03; 60(5):2018-2025. doi: 10.1021/acs.jmedchem.6b01767. [PMID: 28195728]
  • Zhou Meng, Harma Ellens, Joe Bentz. Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells. Drug metabolism and disposition: the biological fate of chemicals. 2017 02; 45(2):190-197. doi: 10.1124/dmd.116.072140. [PMID: 27856526]
  • Steven M Sparks, Huiqiang Zhou, Claudia Generaux, Lindsey Harston, David Moncol, Channa Jayawickreme, Janet Parham, Patrick Condreay, Thomas Rimele. Identification of nonabsorbable inhibitors of the scavenger receptor-BI (SR-BI) for tissue-specific administration. Bioorganic & medicinal chemistry letters. 2016 Apr; 26(8):1901-4. doi: 10.1016/j.bmcl.2016.03.025. [PMID: 26988301]
  • Masayuki Amano, Yasushi Tojo, Pedro Miguel Salcedo-Gómez, Garth L Parham, Prasanth R Nyalapatla, Debananda Das, Arun K Ghosh, Hiroaki Mitsuya. A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro. Antimicrobial agents and chemotherapy. 2015 May; 59(5):2625-35. doi: 10.1128/aac.04757-14. [PMID: 25691652]
  • Ivy Song, Julie Borland, Shuguang Chen, Amanda Peppercorn, Toshihiro Wajima, Stephen C Piscitelli. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrobial agents and chemotherapy. 2014 Nov; 58(11):6696-700. doi: 10.1128/aac.03282-14. [PMID: 25155604]
  • André Mateus, Pär Matsson, Per Artursson. A high-throughput cell-based method to predict the unbound drug fraction in the brain. Journal of medicinal chemistry. 2014 Apr; 57(7):3005-10. doi: 10.1021/jm401963n. [PMID: 24601604]
  • Hari Babu Tatipaka, J Robert Gillespie, Arnab K Chatterjee, Neil R Norcross, Matthew A Hulverson, Ranae M Ranade, Pendem Nagendar, Sharon A Creason, Joshua McQueen, Nicole A Duster, Advait Nagle, Frantisek Supek, Valentina Molteni, Tanja Wenzler, Reto Brun, Richard Glynne, Frederick S Buckner, Michael H Gelb. Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. Journal of medicinal chemistry. 2014 Feb; 57(3):828-35. doi: 10.1021/jm401178t. [PMID: 24354316]
  • April M Barbour, Leonid Gibiansky, Mary Beth Wire. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of clinical pharmacology. 2014 Feb; 54(2):206-14. doi: 10.1002/jcph.205. [PMID: 25272370]
  • Robin Wood, Joseph C Gathe, Naomi Givens, Sangeeta Sedani, Katharine Cheng, Jörg Sievers. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients. HIV clinical trials. 2013 Sep; 14(5):183-91. doi: 10.1310/hct1405-183. [PMID: 24144895]
  • Robert N Helsley, Yipeng Sui, Ni Ai, Se-Hyung Park, William J Welsh, Changcheng Zhou. Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice. Molecular pharmacology. 2013 Jun; 83(6):1190-9. doi: 10.1124/mol.113.085753. [PMID: 23519392]
  • Annie Albin Lumen, Libin Li, Jiben Li, Zeba Ahmed, Zhou Meng, Albert Owen, Harma Ellens, Ismael J Hidalgo, Joe Bentz. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. PloS one. 2013; 8(8):e69394. doi: 10.1371/journal.pone.0069394. [PMID: 23976943]
  • Edward P Acosta, Kay L Limoli, Lan Trinh, Neil T Parkin, Jennifer R King, Jodi M Weidler, Ighovwerha Ofotokun, Christos J Petropoulos. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrobial agents and chemotherapy. 2012 Nov; 56(11):5938-45. doi: 10.1128/aac.00691-12. [PMID: 22964257]
  • Xingrong Liu, Xiao Ding, Gauri Deshmukh, Bianca M Liederer, Cornelis E C A Hop. Use of the cassette-dosing approach to assess brain penetration in drug discovery. Drug metabolism and disposition: the biological fate of chemicals. 2012 May; 40(5):963-9. doi: 10.1124/dmd.111.044420. [PMID: 22328585]
  • David Croteau, Scott Letendre, Brookie M Best, Steven S Rossi, Ronald J Ellis, David B Clifford, Ann C Collier, Benjamin B Gelman, Christina M Marra, Justin McArthur, J Allen McCutchan, Susan Morgello, David M Simpson, Lauren Way, Edmund Capparelli, Igor Grant. Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrobial agents and chemotherapy. 2012 Apr; 56(4):1985-9. doi: 10.1128/aac.05098-11. [PMID: 22290964]
  • Sophie Perrin, Jonathan Cremer, Olivia Faucher, Jacques Reynes, Pierre Dellamonica, Joëlle Micallef, Caroline Solas, Bruno Lacarelle, Charlotte Stretti, Elise Kaspi, Andrée Robaglia-Schlupp, Corinne Nicolino-Brunet, Corine Nicolino-Brunet Catherine Tamalet, Catherine Tamalet, Nicolas Lévy, Isabelle Poizot-Martin, Pierre Cau, Patrice Roll. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study. PloS one. 2012; 7(12):e53035. doi: 10.1371/journal.pone.0053035. [PMID: 23285253]
  • Xianyi Sha, Juan Wu, Yanzuo Chen, Xiaoling Fang. Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation. International journal of nanomedicine. 2012; 7(?):705-12. doi: 10.2147/ijn.s28052. [PMID: 22359449]
  • Jia-Ming Yang, Siu-Po Ip, Yanfang Xian, Ming Zhao, Zhi-Xiu Lin, John Hok Keung Yeung, Raphael Chiu Yeung Chan, Shui-Shan Lee, Chun-Tao Che. Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. PloS one. 2012; 7(2):e31312. doi: 10.1371/journal.pone.0031312. [PMID: 22359586]
  • Maria Salgado, S Alireza Rabi, Karen A O'Connell, Robert W Buckheit, Justin R Bailey, Amina A Chaudhry, Autumn R Breaud, Mark A Marzinke, William Clarke, Joseph B Margolick, Robert F Siliciano, Joel N Blankson. Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology. 2011 Dec; 8(?):97. doi: 10.1186/1742-4690-8-97. [PMID: 22141397]
  • L Ene, D Duiculescu, S M Ruta. How much do antiretroviral drugs penetrate into the central nervous system?. Journal of medicine and life. 2011 Nov; 4(4):432-9. doi: NULL. [PMID: 22514580]
  • M Saumoy, Jm Tiraboschi, M Gutierrez, J Niubó, P Domingo, A Vila, D Podzamczer. Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV medicine. 2011 Aug; 12(7):438-41. doi: 10.1111/j.1468-1293.2010.00898.x. [PMID: 21729229]
  • José Francisco Höfling, Rita Cássia Mardegan, Paula Cristina Anibal, Vivian Fernandes Furletti, Mary Ann Foglio. Evaluation of antifungal activity of medicinal plant extracts against oral Candida albicans and proteinases. Mycopathologia. 2011 Aug; 172(2):117-24. doi: 10.1007/s11046-011-9404-z. [PMID: 21409409]
  • Mayank Mohan Agarwal, Shwaran K Singh, Ravimohan Mavuduru, Arup K Mandal. Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature. Indian journal of urology : IJU : journal of the Urological Society of India. 2011 Jul; 27(3):310-9. doi: 10.4103/0970-1591.85423. [PMID: 22022052]
  • S Halde, A Mungantiwar, M Chintamaneni. Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma. Indian journal of pharmaceutical sciences. 2011 Jul; 73(4):416-21. doi: 10.4103/0250-474x.95626. [PMID: 22707826]
  • Robert T Jacobs, Bakela Nare, Stephen A Wring, Matthew D Orr, Daitao Chen, Jessica M Sligar, Matthew X Jenks, Robert A Noe, Tana S Bowling, Luke T Mercer, Cindy Rewerts, Eric Gaukel, Jennifer Owens, Robin Parham, Ryan Randolph, Beth Beaudet, Cyrus J Bacchi, Nigel Yarlett, Jacob J Plattner, Yvonne Freund, Charles Ding, Tsutomu Akama, Y-K Zhang, Reto Brun, Marcel Kaiser, Ivan Scandale, Robert Don. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS neglected tropical diseases. 2011 Jun; 5(6):e1151. doi: 10.1371/journal.pntd.0001151. [PMID: 21738803]
  • Z Zhang, Xf Liang, Mq Su, Q Liang, Lp Li, Xh Zhang, Xm Wang, X Zhu. Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2011; 19(3):210-5. doi: NULL. [PMID: 22615659]
  • Antonio D'Avolio, Marco Simiele, Marco Siccardi, Lorena Baietto, Mauro Sciandra, Stefano Bonora, Giovanni Di Perri. HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. Journal of pharmaceutical and biomedical analysis. 2010 Sep; 52(5):774-80. doi: 10.1016/j.jpba.2010.02.026. [PMID: 20236784]
  • Roland J W Meesters, Jeroen J A van Kampen, Mariska L Reedijk, Rachel D Scheuer, Lennard J M Dekker, David M Burger, Nico G Hartwig, Albert D M E Osterhaus, Theo M Luider, Rob A Gruters. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Analytical and bioanalytical chemistry. 2010 Sep; 398(1):319-28. doi: 10.1007/s00216-010-3952-9. [PMID: 20632164]
  • Rama Mallipeddi, Lisa Cencia Rohan. Progress in antiretroviral drug delivery using nanotechnology. International journal of nanomedicine. 2010 Aug; 5(?):533-47. doi: 10.2147/ijn.s7681. [PMID: 20957115]
  • Rob Ter Heine, Hilde Rosing, Jos H Beijnen, Alwin D R Huitema. A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. Clinical chemistry and laboratory medicine. 2010 Aug; 48(8):1153-5. doi: 10.1515/cclm.2010.225. [PMID: 20482447]
  • Jeroen J A van Kampen, Mariska L Reedijk, Peter C Burgers, Lennard J M Dekker, Nico G Hartwig, Ineke E van der Ende, Ronald de Groot, Albert D M E Osterhaus, David M Burger, Theo M Luider, Rob A Gruters. Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. PloS one. 2010 Jul; 5(7):e11409. doi: 10.1371/journal.pone.0011409. [PMID: 20625386]
  • Laura Else, Victoria Watson, John Tjia, Andrew Hughes, Marco Siccardi, Saye Khoo, David Back. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Jun; 878(19):1455-65. doi: 10.1016/j.jchromb.2010.03.036. [PMID: 20427248]
  • Mehmet Gumustas, Sibel A Ozkan. Electrochemical evaluation and determination of antiretroviral drug fosamprenavir using boron-doped diamond and glassy carbon electrodes. Analytical and bioanalytical chemistry. 2010 May; 397(1):189-203. doi: 10.1007/s00216-009-3334-3. [PMID: 19998025]
  • Mircea Penescu, Victor Lorin Purcarea, Ioana Sisu, Eugen Sisu. Mass spectrometry and renal calculi. Journal of medicine and life. 2010 Apr; 3(2):128-36. doi: NULL. [PMID: 20968197]
  • Jeffrey F Waring, Rita Ciurlionis, Kennan Marsh, Larry L Klein, David A Degoey, John T Randolph, Brian Spear, Dale J Kempf. Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Archives of toxicology. 2010 Apr; 84(4):263-70. doi: 10.1007/s00204-010-0527-7. [PMID: 20213465]
  • A D Luber, D V Condoluci, P D Slowinski, M Andrews, K Olson, C A Peloquin, K A Pappa, G E Pakes. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV medicine. 2010 Mar; 11(3):193-9. doi: 10.1111/j.1468-1293.2009.00765.x. [PMID: 19863619]
  • Robert J Danaher, Chunmei Wang, Andrew T Roland, Charlotte S Kaetzel, Richard N Greenberg, Craig S Miller. HIV protease inhibitors block oral epithelial cell DNA synthesis. Archives of oral biology. 2010 Feb; 55(2):95-100. doi: 10.1016/j.archoralbio.2009.12.001. [PMID: 20035926]
  • Weerawat Manosuthi, Sasisopin Kiertiburanakul, Wannarat Amornnimit, Wisit Prasithsirikul, Supeda Thongyen, Samruay Nilkamhang, Kiat Ruxrungtham, Somnuek Sungkanuparph. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS research and therapy. 2009 Dec; 6(?):30. doi: 10.1186/1742-6405-6-30. [PMID: 20030841]
  • Jaromir Mikl, Mark S Sulkowski, Yves Benhamou, Douglas Dieterich, Stanislas Pol, Jürgen Rockstroh, Patrick A Robinson, Mithun Ranga, Jerry O Stern. Hepatic profile analyses of tipranavir in Phase II and III clinical trials. BMC infectious diseases. 2009 Dec; 9(?):203. doi: 10.1186/1471-2334-9-203. [PMID: 20003457]
  • Sylvie Quaranta, Christian Woloch, Alexandre Paccou, Madeleine Giocanti, Caroline Solas, Bruno Lacarelle. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Therapeutic drug monitoring. 2009 Dec; 31(6):695-702. doi: 10.1097/ftd.0b013e3181c05adf. [PMID: 19865000]
  • Andrew Hill, Jasper van der Lugt, Will Sawyer, Marta Boffito. How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS (London, England). 2009 Nov; 23(17):2237-45. doi: 10.1097/qad.0b013e328332c3a5. [PMID: 19809270]
  • J Martin, G Deslandes, E Dailly, C Renaud, V Reliquet, F Raffi, P Jolliet. A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Oct; 877(27):3072-82. doi: 10.1016/j.jchromb.2009.07.031. [PMID: 19699694]
  • Valerio Tozzi, Pietro Balestra, Maria Flora Salvatori, Chrysoula Vlassi, Giuseppina Liuzzi, Maria Letizia Giancola, Marinella Giulianelli, Pasquale Narciso, Andrea Antinori. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. Journal of acquired immune deficiency syndromes (1999). 2009 Sep; 52(1):56-63. doi: 10.1097/qai.0b013e3181af83d6. [PMID: 19731418]
  • Jean-Michel Molina, Mounir Ait-Khaled, Roberto Rinaldi, Giovanni Penco, Jean-Guy Baril, Roberto Cauda, Vicente Soriano, Gilles Pialoux, Mary Beth Wire, Yu Lou, Naomi Givens, Charles Craig, W Garrett Nichols, Inês Barbosa, Jane Yeo. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. The Journal of antimicrobial chemotherapy. 2009 Aug; 64(2):398-410. doi: 10.1093/jac/dkp198. [PMID: 19515730]
  • Marypeace McRae, Patrick G Clay, Peter L Anderson, Alan G Glaros. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacotherapy. 2009 Aug; 29(8):937-42. doi: 10.1592/phco.29.8.937. [PMID: 19637947]
  • Laura Dickinson, Marta Boffito, David Back, Laura Waters, Laura Else, Geraint Davies, Saye Khoo, Anton Pozniak, Leon Aarons. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. The Journal of antimicrobial chemotherapy. 2009 Jun; 63(6):1233-43. doi: 10.1093/jac/dkp102. [PMID: 19329800]
  • Jane M Sayer, John M Louis. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins. 2009 May; 75(3):556-68. doi: 10.1002/prot.22271. [PMID: 18951411]
  • David A Parks, H Clay Jennings, Christopher Taylor, Gary E Pakes, Edward P Acosta. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II). HIV clinical trials. 2009 May; 10(3):160-7. doi: 10.1310/hct1003-160. [PMID: 19632955]
  • Francesca Gatti, Paola Nasta, Arianna Loregian, Massimo Puoti, Alessandro Matti, Silvana Pagni, Daniel Gonzalez de Requena, Katiela Prestini, Saverio G Parisi, Stefano Bonora, Giorgio Palù, Giampiero Carosi. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. The Journal of antimicrobial chemotherapy. 2009 Mar; 63(3):575-8. doi: 10.1093/jac/dkn525. [PMID: 19151039]
  • R ter Heine, M Davids, H Rosing, E C M van Gorp, J W Mulder, Y T van der Heide, J H Beijnen, A D R Huitema. Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Feb; 877(5-6):575-80. doi: 10.1016/j.jchromb.2009.01.011. [PMID: 19168402]
  • Kate McKeage, Caroline M Perry, Susan J Keam. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009; 69(4):477-503. doi: 10.2165/00003495-200969040-00007. [PMID: 19323590]
  • Carmen D Zorrilla, Vivian Tamayo-Agrait. Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. HIV/AIDS (Auckland, N.Z.). 2009; 1(?):41-53. doi: 10.2147/hiv.s6326. [PMID: 22096378]
  • Lívia O Santos, Fernanda A Marinho, Ellen F Altoé, Bianca S Vitório, Carlos R Alves, Constança Britto, Maria Cristina M Motta, Marta H Branquinha, André L S Santos, Claudia M d'Avila-Levy. HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PloS one. 2009; 4(3):e4918. doi: 10.1371/journal.pone.0004918. [PMID: 19325703]
  • Antonella Mandas, Eugenio Luigi Iorio, Maria Gabriella Congiu, Cinzia Balestrieri, Antonello Mereu, Daniela Cau, Sandra Dessì, Nicoletta Curreli. Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. Journal of biomedicine & biotechnology. 2009; 2009(?):749575. doi: 10.1155/2009/749575. [PMID: 19884983]
  • Sarah Hochman, Kami Kim. The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study. Interdisciplinary perspectives on infectious diseases. 2009; 2009(?):617954. doi: 10.1155/2009/617954. [PMID: 19680452]
  • Laure Elens, Sophie Veriter, Vincent Di Fazio, Roger Vanbinst, Daniel Boesmans, Pierre Wallemacq, Vincent Haufroid. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clinical chemistry. 2009 Jan; 55(1):170-4. doi: 10.1373/clinchem.2008.108647. [PMID: 19028822]
  • Eoin J Cotter, Patrick W Mallon, Peter P Doran. Is PPARγ a prospective player in HIV-1-associated bone disease?. PPAR research. 2009; 2009(?):421376. doi: 10.1155/2009/421376. [PMID: 19325916]
  • Ronald J Ellis, Jennifer Marquie-Beck, Patrick Delaney, Terry Alexander, David B Clifford, Justin C McArthur, David M Simpson, Christopher Ake, Ann C Collier, Benjamin B Gelman, J Allen McCutchan, Susan Morgello, Igor Grant. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Annals of neurology. 2008 Nov; 64(5):566-72. doi: 10.1002/ana.21484. [PMID: 19067367]
  • Linda Wittkop, Daniel Commenges, Isabelle Pellegrin, Dominique Breilh, Didier Neau, Denis Lacoste, Jean-Luc Pellegrin, Geneviève Chêne, François Dabis, Rodolphe Thiébaut. Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy. BMC medical research methodology. 2008 Oct; 8(?):68. doi: 10.1186/1471-2288-8-68. [PMID: 18945369]
  • M Isabel Gonzalez-Tome, Jose Tomas Ramos Amador, M Jose Mellado Peña, M Luisa Navarro Gomez, Pablo Rojo Conejo, Pablo Martin Fontelos. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. BMC infectious diseases. 2008 Oct; 8(?):144. doi: 10.1186/1471-2334-8-144. [PMID: 18945352]
  • Aurélie Fayet, Alexandre Béguin, Begona Martinez de Tejada, Sara Colombo, Matthias Cavassini, Stefan Gerber, Chin B Eap, Amalio Telenti, Thierry Buclin, Jérôme Biollaz, Laurent A Decosterd. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Therapeutic drug monitoring. 2008 Aug; 30(4):511-22. doi: 10.1097/ftd.0b013e3181817318. [PMID: 18641538]
  • Ying-Jun Cao, Patrick F Smith, Mary Beth Wire, Yu Lou, Charles T Lancaster, Roger C Causon, George E Bigelow, Elizabeth Martinez, Edward J Fuchs, Christine Radebaugh, Sarah McCabe, Craig W Hendrix. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Pharmacotherapy. 2008 Jul; 28(7):863-74. doi: 10.1592/phco.28.7.863. [PMID: 18576901]
  • Aurélie Barrail-Tran, Laurence Morand-Joubert, Gwendoline Poizat, Gilles Raguin, Clotilde Le Tiec, François Clavel, Elisabeth Dam, Geneviève Chêne, Pierre-Marie Girard, Anne-Marie Taburet. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrobial agents and chemotherapy. 2008 May; 52(5):1642-6. doi: 10.1128/aac.01314-07. [PMID: 18285478]
  • Sharon L Walmsley, Christine Katlama, Adriano Lazzarin, Keikawus Arestéh, Gerald Pierone, Gary Blick, Margaret Johnson, Ulrich Meier, Thomas R MacGregor, Johnathan G Leith. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). Journal of acquired immune deficiency syndromes (1999). 2008 Apr; 47(4):429-40. doi: 10.1097/qai.0b013e318160a529. [PMID: 18176328]
  • Olga Delgado, Melchor Riera, Javier Murillas, Pere Ventayol. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir]. Enfermedades infecciosas y microbiologia clinica. 2008 Mar; 26(3):182-3. doi: 10.1157/13116760. [PMID: 18358222]
  • Stefania Notari, Carmine Mancone, Tonino Alonzi, Marco Tripodi, Pasquale Narciso, Paolo Ascenzi. Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2008 Mar; 863(2):249-57. doi: 10.1016/j.jchromb.2008.01.009. [PMID: 18258495]
  • Peng Hsiao, Tot Bui, Rodney J Y Ho, Jashvant D Unadkat. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug metabolism and disposition: the biological fate of chemicals. 2008 Mar; 36(3):481-4. doi: 10.1124/dmd.107.018176. [PMID: 18057117]
  • Qing Ma, Alan Forrest, Susan L Rosenkranz, Michael F Para, Kevin E Yarasheski, Richard C Reichman, Gene D Morse. Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharmaceutics & drug disposition. 2008 Mar; 29(2):91-101. doi: 10.1002/bdd.597. [PMID: 18041735]
  • Jean Ruelle, François Roman, Anne-Thérèse Vandenbroucke, Christine Lambert, Katrien Fransen, Fedoua Echahidi, Denis Piérard, Chris Verhofstede, Kristel Van Laethem, Marie-Luce Delforge, Dolorès Vaira, Jean-Claude Schmit, Patrick Goubau. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database. BMC infectious diseases. 2008 Feb; 8(?):21. doi: 10.1186/1471-2334-8-21. [PMID: 18304321]
  • Tamara Nora, Francine Bouchonnet, Béatrice Labrosse, Charlotte Charpentier, Fabrizio Mammano, François Clavel, Allan J Hance. Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology. 2008 Feb; 5(?):23. doi: 10.1186/1742-4690-5-23. [PMID: 18312646]
  • Eric Dailly, François Raffi, Charlotte Biron, C Allavena, P Jolliet. Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Fundamental & clinical pharmacology. 2008 Feb; 22(1):101-4. doi: 10.1111/j.1472-8206.2007.00556.x. [PMID: 18251726]
  • Antje Feicke, Katharina M Rentsch, Daniel Oertle, Räto T Strebel. Same patient, new stone composition: amprenavir urinary stone. Antiviral therapy. 2008; 13(5):733-4. doi: NULL. [PMID: 18771058]
  • Ighovwerha Ofotokun, Edward P Acosta, Jeffrey L Lennox, Yi Pan, Kirk A Easley. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy. 2008 Jan; 28(1):74-81. doi: 10.1592/phco.28.1.74. [PMID: 18154477]
  • N Janus, V Launay-Vacher, H Izzedine, S Karie, I Laville, G Deray. [Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency]. Medecine et maladies infectieuses. 2007 Dec; 37(12):832-4. doi: 10.1016/j.medmal.2006.11.017. [PMID: 17997253]
  • Enric Pedrol, Elisabet Deig. Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'. AIDS (London, England). 2007 Nov; 21(18):2566. doi: 10.1097/qad.0b013e3282f13a62. [PMID: 18025906]
  • Antonio D'Avolio, Marco Siccardi, Mauro Sciandra, Lorena Baietto, Baietto Lorena, Stefano Bonora, Laura Trentini, Giovanni Di Perri. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Nov; 859(2):234-40. doi: 10.1016/j.jchromb.2007.10.003. [PMID: 17964231]
  • Manon J van der Lee, Audrey A M Blenke, Gerard A Rongen, Corrien P W G M Verwey-van Wissen, Peter P Koopmans, Cristina Pharo, David M Burger. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrobial agents and chemotherapy. 2007 Nov; 51(11):4098-104. doi: 10.1128/aac.01243-06. [PMID: 17846135]
  • Jawad Kiani, Sardar Z Imam. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutrition journal. 2007 Oct; 6(?):33. doi: 10.1186/1475-2891-6-33. [PMID: 17971226]
  • Elena Seminari, Anna De Bona, Gianluca Gentilini, Laura Galli, Giulia Schira, Nicola Gianotti, Caterina Uberti-Foppa, Armando Soldarini, Fernanda Dorigatti, Adriano Lazzarin, Antonella Castagna. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. The Journal of antimicrobial chemotherapy. 2007 Oct; 60(4):831-6. doi: 10.1093/jac/dkm282. [PMID: 17684056]
  • A D Luber, R Brower, D Kim, R Silverman, C A Peloquin, I Frank. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV medicine. 2007 Oct; 8(7):457-64. doi: 10.1111/j.1468-1293.2007.00496.x. [PMID: 17760738]
  • Leah Tong, Truc K Phan, Kelly L Robinson, Darius Babusis, Robert Strab, Siddhartha Bhoopathy, Ismael J Hidalgo, Gerald R Rhodes, Adrian S Ray. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrobial agents and chemotherapy. 2007 Oct; 51(10):3498-504. doi: 10.1128/aac.00671-07. [PMID: 17664327]
  • Joachim Brouwers, Jan Tack, Patrick Augustijns. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharmaceutical research. 2007 Oct; 24(10):1862-9. doi: 10.1007/s11095-007-9307-3. [PMID: 17443397]
  • Richard Hazen, Robert Harvey, Robert Ferris, Charles Craig, Phillip Yates, Philip Griffin, John Miller, Istvan Kaldor, John Ray, Vincente Samano, Eric Furfine, Andrew Spaltenstein, Michael Hale, Roger Tung, Marty St Clair, Mary Hanlon, Lawrence Boone. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrobial agents and chemotherapy. 2007 Sep; 51(9):3147-54. doi: 10.1128/aac.00401-07. [PMID: 17620375]
  • Erica Bastiani, Fabio Benedetti, Federico Berti, Pietro Campaner, Elena Donadel, Michela Montagna, Mario Regazzi, Serena Rinaldi, Adriano Savoini, Romina Venturini. Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir. Journal of immunological methods. 2007 Aug; 325(1-2):35-41. doi: 10.1016/j.jim.2007.05.009. [PMID: 17597142]
  • Mary B Wire, Charles H Ballow, Julie Borland, Mark J Shelton, Yu Lou, Geoffrey Yuen, Jiang Lin, Eric W Lewis. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged. Antimicrobial agents and chemotherapy. 2007 Aug; 51(8):2982-4. doi: 10.1128/aac.00008-07. [PMID: 17517848]
  • Bruno Hoen, David A Cooper, Fiona C Lampe, Luc Perrin, Nathan Clumeck, Andrew N Phillips, Li-Ean Goh, Stefan Lindback, Daniel Sereni, Brian Gazzard, Julio Montaner, Hans-Jurgen Stellbrink, Adriano Lazzarin, Diane Ponscarme, Shlomo Staszewski, Lars Mathiesen, Don Smith, Robert Finlayson, Rainer Weber, Laurence Wegmann, George Janossy, Sabine Kinloch-de Loes. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Aug; 45(3):381-90. doi: 10.1086/519428. [PMID: 17599319]
  • Heidi M Crane, Bryan Kestenbaum, Robert D Harrington, Mari M Kitahata. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS (London, England). 2007 Jul; 21(11):1431-9. doi: 10.1097/qad.0b013e3281fc9320. [PMID: 17589189]
  • Vincenzo Spagnuolo, Gianluca Gentilini, Anna De Bona, Laura Galli, Caterina Uberti-Foppa, Armando Soldarini, Fernanda Dorigatti, Elena Seminari. Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels. The new microbiologica. 2007 Jul; 30(3):279-82. doi: . [PMID: 17802909]
  • Susan L Rosenkranz, Kevin E Yarasheski, Michael F Para, Richard C Reichman, Gene D Morse. Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. Metabolic syndrome and related disorders. 2007 Jun; 5(2):163-73. doi: 10.1089/met.2006.0034. [PMID: 18007962]
  • Olanrewaju Okusanya, Alan Forrest, Robin DiFrancesco, Sanela Bilic, Susan Rosenkranz, Michael F Para, Elizabeth Adams, Kevin E Yarasheski, Richard C Reichman, Gene D Morse. Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrobial agents and chemotherapy. 2007 May; 51(5):1822-6. doi: 10.1128/aac.00570-06. [PMID: 17283195]
  • Dennis R Weller, Richard C Brundage, Henry H Balfour, Heather E Vezina. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Apr; 848(2):369-73. doi: 10.1016/j.jchromb.2006.10.022. [PMID: 17081812]
  • Sun Ok Choi, Naser L Rezk, Angela D M Kashuba. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. Journal of pharmaceutical and biomedical analysis. 2007 Mar; 43(4):1562-7. doi: 10.1016/j.jpba.2006.11.017. [PMID: 17236737]
  • Peter J Ruane, Andrew D Luber, Mary Beth Wire, Yu Lou, Mark J Shelton, C Tracey Lancaster, Keith A Pappa. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial agents and chemotherapy. 2007 Feb; 51(2):560-5. doi: 10.1128/aac.00560-06. [PMID: 17088488]
  • Claire Lagathu, Brenda Eustace, Matthieu Prot, Dan Frantz, Yong Gu, Jean-Philippe Bastard, Mustapha Maachi, Stephane Azoulay, Michael Briggs, Martine Caron, Jacqueline Capeau. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antiviral therapy. 2007; 12(4):489-500. doi: . [PMID: 17668557]
  • Monique Nijhuis, Noortje M van Maarseveen, Stephane Lastere, Pauline Schipper, Eoin Coakley, Bärbel Glass, Mirka Rovenska, Dorien de Jong, Colombe Chappey, Irma W Goedegebuure, Gabrielle Heilek-Snyder, Dominic Dulude, Nick Cammack, Lea Brakier-Gingras, Jan Konvalinka, Neil Parkin, Hans-Georg Kräusslich, Francoise Brun-Vezinet, Charles A B Boucher. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS medicine. 2007 Jan; 4(1):e36. doi: 10.1371/journal.pmed.0040036. [PMID: 17227139]
  • Anne-Kathrin Gehrig, Gerd Mikus, Walter E Haefeli, Jürgen Burhenne. Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid communications in mass spectrometry : RCM. 2007; 21(16):2704-16. doi: 10.1002/rcm.3138. [PMID: 17639576]
  • Rob ter Heine, Carolien G Alderden-Los, Hilde Rosing, Michel J X Hillebrand, Eric C M van Gorp, Alwin D R Huitema, Jos H Beijnen. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2007; 21(15):2505-14. doi: 10.1002/rcm.3119. [PMID: 17610214]